medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2012, Number 600

<< Back Next >>

Rev Med Cos Cen 2012; 69 (600)

Herpes Zoster y su principal complicación: Neuralgia Postherpética

Mena RMJ

Language: Spanish
References: 18
Page: 9-13
PDF size: 156.67 Kb.


ABSTRACT

Herpes Zoster is caused by reactivation of latent Varicella Zoster Virus (VZV) in sensory nerve ganglia. Aging and immunosuppressive conditions result in a decline in VZVspecific cell mediated immunity that predisposes to zoster. It presents as a distinctive, painful vesicular rash appearing in a unilateral, dermatomal distribution and post-herpetic neuralgia is the most common complication of this disease. Treatment of herpes zoster and post-herpetic neuralgia is complex. The vaccine for the prevention of herpes zoster has been licensed for individuals 60 years of age and older, multidisciplinary interventions and the combination of several drugs are required during the acute and chronic phases to improve the quality of life and the functional capacity of the patient who suffers this illness.


REFERENCES

  1. Arvin A. Aging, Immunity, and the Varicella–Zoster Virus. N Engl J Med.2005 Jun 2; 352 (22):2266-7.

  2. Bennett GJ, Watson CPN. Herpes zoster and postherpetic neuralgia: Past, present and future. Pain Res Manage. 2009; 14 (4): 275-282.

  3. Boivin G, Jovey R, Elliott CT, Patrick DM. Management and prevention of Herpes Zoster: A Canadian perspective. Can J Infect Dis Med Microbiol. 2010; 21 (1): 45-52.

  4. Cappuzzo KA. Treatment of postherpetic neuralgia: focus on pregabalin. Clinical Interventions in Aging 2009; 4:17-23.

  5. Chua JV, Chen WH †. Herpes Zoster Vaccine for the elderly: boosting immunity. Aging health. 2010 April 1; 6 (2): 169-176.

  6. Fashner J, Bell AL. Herpes Zoster and Postherpetic Neuralgia: Prevention and Management. Am Fam Physician.2011 Jun 15; 83,(12):1432-1437.

  7. Gilden D †, Nagel MA, Mahalingam R, Mueller NH, Brazeau EA, Pugazhenthi S, Cohrs RJ. Clinical and molecular aspects of varicella zoster virus infection. Future Neurol. 2009 January 1; 4 (1): 103-117.

  8. Gnann JW, Whitley RJ. Herpes Zoster. N Engl J Med. August 1, 2002; 347 (5) 340-346.

  9. Gowrishankar K, Steain M, Cunningham AL, Rodríguez M, Blumbergs P, Slobedman B and Abendroth A. Characterization of the Host Immune Response in Human Ganglia after Herpes Zoster. Journal of Virology. Sept.2010, 84(17): 8861-8870.

  10. Jensen-Dahm C, Rowbotham MC, Petersen KL. Effect of a single dose of pregabalin on herpes zoster pain. Trials 2011 Feb 28;12:55.

  11. Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE and Weinke T. The impact of herpes zoster and postherpetic neuralgia on quality-of.life. BMC Medicine. 2010, 8: 37.

  12. Johnson R.W, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract. September 2009; 63,(9): 1386-1391.

  13. Kimberlin DW, Whitley RJ. Varicella– Zoster Vaccine for the Prevention of Herpes Zoster. N Engl J Med. 2007 March 29; 356:1338-1343.

  14. Noh TW, Park SH, Kang YS, Lee UH, Park HS, Jang SJ. Morphea Developing at the Site of Healed Herpes Zoster. Ann Dermatol. 2011. 23(2):242-245.

  15. Opstelten W, Eekhof J, Neven AK, Verheij T. Treatment of herpes zoster. Canadian Family Physician. March 2008; 54:373-377.

  16. Park K-C, Yoon S-S, Yoon J-E, Rhee H-Y. A Case of Herpes Zoster Ophthalmicus with Isolated Trochlear Nerve Involvement. J Clin Neurol 2011; 7: 47-49.

  17. The American Society of Anesthesiologists. Practice Guidelines for Chronic Pain Management. Anesthesiology 2010; 112:810-33.

  18. Yawn BP, Wollan PC, Kurland MJ, St. Sauver JL and Saddier P. Herpes Zoster Recurrences More Frequent Than Previously Reported. Mayo Clin Proc. February 2011; 86 (2): 88-93.




2020     |     www.medigraphic.com